|Tested species reactivity||Human, Rat|
|Published species reactivity||Human, Mouse|
|Host / Isotype||Mouse / IgG2b, kappa|
|Immunogen||Keratin preparation from rat enterocytes|
|Storage buffer||tissue culture supernatant|
|Contains||0.09% sodium azide|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|Immunofluorescence (IF)||Assay Dependent|
|Immunohistochemistry (Paraffin) (IHC (P))||1:40-1:80|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Immunohistochemistry (IHC)||See 8 publications below|
MA5-13539 targets Cytokeratin 17 in IF and IHC (P) applications and shows reactivity with Human and Rat samples.
The MA5-13539 immunogen is keratin preparation from rat enterocytes.
The type I keratin 17 (K17) shows a peculiar localization in human epithelial appendages including hair follicles, which undergo a growth cycle throughout adult life. Additionally K17 is induced, along with K6 and K16, early after acute injury to human skin. Predominant expression of K17 and the frequent expression of K8 and K19, with little K6/K16 and K1/K10 expression are the characteristic features of basal cell carcinomas (BCC), suggesting that BCC is differentiated towards undifferentiated follicular epithelia, most probably hair bulge cells.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
High level PHGDH expression in breast is predominantly associated with keratin 5-positive cell lineage independently of malignancy.
MA5-13539 was used in immunohistochemistry to study the PHGDH expression in mammary tissue from the patients with triple negative breast cancer
|Gromova I,Gromov P,Honma N,Kumar S,Rimm D,Talman ML,Wielenga VT,Moreira JM||Molecular oncology (9:1636)||2015|
Impaired wound repair in adult endoglin heterozygous mice associated with lower NO bioavailability.
MA5-13539 was used in immunohistochemistry to study the role of reduced NO levels in the defective skin wound healing observed in adult endoglin (+/-) heterozygous mice
|Pérez-Gómez E,Jerkic M,Prieto M,del Castillo G,Martín-Villar E,Letarte M,Bernabeu C,Pérez-Barriocanal F,Quintanilla M,López-Novoa JM||The Journal of investigative dermatology (134:247)||2014|
CD200-expressing human basal cell carcinoma cells initiate tumor growth.
MA5-13539 was used in immunohistochemistry to study the abiliy of the CD200-positive human basal cell carcinoma cells to initiate tumor growth
|Colmont CS,Benketah A,Reed SH,Hawk NV,Telford WG,Ohyama M,Udey MC,Yee CL,Vogel JC,Patel GK||Proceedings of the National Academy of Sciences of the United States of America (110:1434)||2013|
Triple-negative breast cancer: immunohistochemical correlation with basaloid markers and prognostic value of survivin.
MA5-13539 was used in immunohistochemistry to study the prognostic value of survivin in patients with basaloid triplet-negative breast cancer
|Dogu GG,Ozkan M,Ozturk F,Dikilitas M,Er O,Ozturk A||Medical oncology (Northwood, London, England) (27:34)||2010|
Omics-based profiling of carcinoma of the breast and matched regional lymph node metastasis.
MA5-13539 was used in immunohistochemistry to investigate the relationship between axillary lymph node metastases and primary breast tumors
|Li J,Gromov P,Gromova I,Moreira JM,Timmermans-Wielenga V,Rank F,Wang K,Li S,Li H,Wiuf C,Yang H,Zhang X,Bolund L,Celis JE||Proteomics (8:5038)||2008|
Keratin profiling in the developing human prostate. A different approach to understanding epithelial lineage.
MA5-13539 was used in immunohistochemistry to investigate the distribution of keratin in prostate during development
|Trompetter M,Smedts F,van der Wijk J,Schoots C,de Jong HJ,Hopman A,de la Rosette J||Anticancer research (28:237)||2008|
Basoluminal carcinoma: a new biologically and prognostically distinct entity between basal and luminal breast cancer.
MA5-13539 was used in immunohistochemistry to study the characteristics of basoluminal carcinoma
|Laakso M,Tanner M,Nilsson J,Wiklund T,Erikstein B,Kellokumpu-Lehtinen P,Malmström P,Wilking N,Bergh J,Isola J||Clinical cancer research : an official journal of the American Association for Cancer Research (12:4185)||2006|
Cytokeratin expression in lichen amyloidosus and macular amyloidosis.
MA5-13539 was used in immunohistochemistry to investigate the expression of cytokeratins in lichen and macular amyloidosis and their diagnostic value
|Apaydin R,Gürbüz Y,Bayramgürler D,Müezzinoglu B,Bilen N||Journal of the European Academy of Dermatology and Venereology : JEADV (18:305)||2004|